Loading company…
Gaithersburg biotech developing protein-based nanoparticle vaccines for infectious diseases, including COVID-19.
Founded in 1987 and headquartered in Gaithersburg, US, Novavax develops vaccines using its protein-based nanoparticle technology, with products including the COVID-19 vaccine Nuvaxovid and a combination COVID-19 and influenza vaccine. Its products are aimed mainly at public health markets, including government health agencies and health organizations. The company reported revenue of USD 682.16 mn and EBITDA of USD -200.44 mn for 2024. It raised USD 255.00 mn in a PIPE on December 15, 2022, with investors including RA Capital, and CEO Stanley Erck leads the company.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in